134 results
424B5
MDGL
Madrigal Pharmaceuticals Inc
7 May 24
Prospectus supplement for primary offering
4:29pm
) on the net gain derived from the disposition, which may be offset by U.S. source capital losses of the non-U.S. holder, if any (even though
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals Inc
7 May 24
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7:06am
partially offset by funding of operations.
Conference Call and Webcast
At 8 a.m. EDT today, May 7, 2024, the Company will host a webcast to review its
424B5
MDGL
Madrigal Pharmaceuticals Inc
20 Mar 24
Prospectus supplement for primary offering
4:06pm
treaty) on the net gain derived from the disposition, which may be offset by U.S. source capital losses of the non-U.S. holder, if any; or
our common
424B5
bkxcqscv6pl wtcgea6
18 Mar 24
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
dh78mb64vuh v2j
28 Feb 24
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
7:01am
424B5
quv1t pvot18a
2 Oct 23
Prospectus supplement for primary offering
5:10pm
424B5
um6be ht2z2
28 Sep 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
uynt3nn
8 Aug 23
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results
8:00am
424B5
kspai b9cyfmxlw
9 May 23
Prospectus supplement for primary offering
9:02am
8-K
EX-99.1
hf2br
9 May 23
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
sk48 qa360yg6dn3
3 Nov 22
Presentations and Reports 2022 Third Quarter Financial Results
8:01am